Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Presented By Halle Moore at 2014 ASCO Annual Meeting
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.
Slide 1
Presented By Amy Abernethy at 2014 ASCO Annual Meeting
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Presented By Mario Sznol at 2014 ASCO Annual Meeting
